Hexarelin for Growth Hormone Pulsatile Release

Candidate profile

Adults with documented or clinically suspected GH deficiency — age-related somatopause or secondary GH deficiency from pituitary suppression — who need the strongest possible GH pulse amplitude from a secretagogue rather than a gentle, sustained elevation.

Hexarelin produces the largest GH release of any GHRP studied in humans — exceeding GHRP-6, GHRP-2, and ipamorelin per dose. This makes it appropriate for individuals who have tried milder GHRPs with inadequate response, or for short-duration protocols where maximum GH stimulation is the goal.

Approach

Subcutaneous hexarelin administration to activate the ghrelin/GHS-R1a receptor, triggering a robust GH pulse from the anterior pituitary. Hexarelin's potency comes with a trade-off that defines the entire protocol strategy: receptor desensitization. Unlike ipamorelin (which shows minimal desensitization), hexarelin progressively downregulates the GHS receptor with sustained use, typically reaching clinically relevant attenuation by week 4. The protocol must be designed around this pharmacological reality.

Protocol design

Primary peptide: Hexarelin, 100–200 mcg per dose

Route: Subcutaneous injection (abdomen or deltoid)

Frequency: Twice daily — first dose upon waking (fasted), second dose 30–60 minutes before sleep

Starting dose: 100 mcg for the first week, then increase to 200 mcg if tolerated

Cycle length: 4 weeks on, 4 weeks off. The off period is non-negotiable — continued use beyond 4 weeks yields diminishing GH release with persistent side effects.

Fasting requirement: Both doses in a low-insulin state. Morning: before breakfast. Evening: at least 2 hours post-meal.

During the off period: Switch to ipamorelin (100–200 mcg, same schedule) to maintain moderate GH support without further GHS-R desensitization, or take a complete peptide break.

Timeline & milestones

Days 1–3: Peak GH response. GH levels may reach 30–50 ng/mL post-injection — substantially higher than physiological nocturnal peaks (~10–20 ng/mL in young adults).

Week 1–2: Functional effects emerge — improved sleep quality, enhanced recovery, increased well-being. Transient water retention and mild joint stiffness indicate robust IGF-1 elevation.

Weeks 3–4: Desensitization onset. By week 4, GH release may be 50–70% of the initial response. This is expected pharmacology, not protocol failure. This is when the cycle ends.

Off period (weeks 5–8): GHS-R receptor density normalizes. Tissue-remodeling effects continue as IGF-1 remains elevated after GH pulses cease.

Monitoring

• IGF-1 levels: Baseline, week 2, and post-cycle (week 6). IGF-1 is the best surrogate for integrated GH exposure — it reflects cumulative GH secretion rather than single-pulse amplitude
• Prolactin and cortisol: Hexarelin stimulates both — more so than ipamorelin. Check baseline and week 2. Prolactin elevation >2x upper normal or cortisol dysregulation warrants dose reduction
• Fasting glucose: GH antagonizes insulin; monitor for glucose elevation, particularly in insulin-resistant individuals
• Subjective recovery and sleep quality: Track daily — these are the most sensitive early indicators of GH response
• Body composition: DEXA at baseline and after 2 complete cycles (approximately 4 months) for objective assessment

When to adjust

• Prolactin elevation with symptoms (galactorrhea, decreased libido): Reduce dose to 100 mcg or switch to ipamorelin. Hexarelin's prolactin effect is its primary disadvantage relative to other GHRPs.
• Excessive water retention or carpal tunnel symptoms: Reduce dose — GH/IGF-1 levels are exceeding the individual's comfortable range.
• Significant hunger increase: Hexarelin activates ghrelin receptors. If hunger management is difficult, consider ipamorelin or GHRP-2, which have less appetite stimulation.
• Desensitization before week 4: End the cycle early. Pushing through desensitization wastes peptide and prolongs receptor downregulation.
• No GH response at 200 mcg: Consider pituitary insufficiency — exogenous GH may be the appropriate alternative.